upadacitinib

Overview

Upadacitinib is a small-molecule, once-daily oral selective Janus kinase 1 (JAK1) inhibitor developed by AbbVie and classified under the Anatomical Therapeutic Chemical (ATC) code L04 (immunosuppressants). It exerts its anti-inflammatory effects by preferentially blocking JAK1, a key intracellular signaling kinase that mediates downstream activation of the JAK/STAT pathway in response to numerous proinflammatory cytokines, including IL-4, IL-13, and IL-17A. By selectively targeting JAK1 over other JAK family members, upadacitinib aims to achieve broad immunomodulatory efficacy while minimizing off-target effects associated with pan-JAK inhibition. The drug is formulated as an extended-release tablet and has received regulatory approval for multiple immune-mediated inflammatory diseases, including moderate-to-severe atopic dermatitis (AD) in adults and adolescents, Crohn's disease (CD), and other conditions in which dysregulated cytokine signaling is central to pathophysiology. Its selectivity profile distinguishes it from earlier, less selective JAK inhibitors such as tofacitinib and baricitinib, positioning it as a next-generation therapeutic option in the JAK inhibitor class.

The pharmacological rationale for upadacitinib rests on the central role of JAK1 in transducing signals from type I, II, and III cytokine receptors implicated in inflammatory skin and gastrointestinal diseases. Compared with biologic agents such as dupilumab — which neutralizes the IL-4 receptor alpha chain — upadacitinib provides a broader suppression of multiple cytokine axes through a single oral agent, potentially offering advantages in patients with complex or refractory inflammatory phenotypes. Its inhibition of JAK1-STAT signaling interrupts the expression of inflammatory mediators, including proinflammatory cytokines that sustain chronic tissue inflammation, making it a versatile candidate across a spectrum of immune-mediated diseases.

Focus of Latest Publications

Recent publications on upadacitinib have focused on its long-term efficacy, safety, comparative performance, and real-world use across inflammatory diseases. In rheumatoid arthritis, the ongoing SELECT-COMPARE study is reporting 7-year data comparing upadacitinib with adalimumab, extending evaluation of both safety and efficacy over prolonged treatment. In atopic dermatitis, multiple studies continue to examine upadacitinib as a selective JAK1 inhibitor, including a 6-year randomized clinical trial safety analysis and a 140-week assessment of patient-reported outcomes from the Measure Up 1 and Measure Up 2 trials, reflecting sustained interest in both long-term tolerability and deep clinical benefit.

Comparative effectiveness studies have also examined upadacitinib against other targeted therapies. A structured benefit-risk assessment based on the 24-week Heads Up trial compared dupilumab and upadacitinib in adults with moderate-to-severe atopic dermatitis, using multicriteria decision analysis to weigh multiple patient-relevant endpoints. Another multicentre real-world study from Italy evaluated longitudinal response trajectories in routine practice among patients with atopic dermatitis treated with dupilumab or upadacitinib, aiming to characterize how treatment responses evolve over time. In ulcerative colitis, a multicenter real-world cohort study compared tofacitinib, filgotinib, and upadacitinib in patients refractory or intolerant to at least one advanced therapy, while in Crohn’s disease the Eneida Registry study assessed real-world effectiveness, safety, and treatment persistence of upadacitinib.

Several publications addressed safety and pharmacologic performance. A multinational retrospective cohort study of Janus kinase inhibitors in skin immune-mediated inflammatory diseases included upadacitinib among the agents evaluated and found no increased risk of mortality, major adverse cardiovascular events, venous thromboembolism, or malignancy over 2 years compared with conventional systemic agents. A bioequivalence study in healthy Chinese subjects compared two extended-release 15 mg tablet formulations of upadacitinib under fasting and postprandial conditions and found both formulations bioequivalent, with only mild drug-related adverse events and no serious adverse events. In addition, a case report described successful use of upadacitinib in tofacitinib-refractory scleritis associated with rheumatoid arthritis and ulcerative colitis, with renewed remission and sustained ocular control after switching to the selective JAK1 inhibitor.

Experimental work has also explored upadacitinib in combination strategies for inflammatory skin disease. One study designed a pH-responsive hydrogel co-delivering CCR7-targeting siRNA and upadacitinib to simultaneously inhibit immune cell chemotaxis and local inflammatory signaling in psoriasis and atopic dermatitis mouse models. This approach reduced keratinocyte proliferation, inflammatory signaling, skin lesions, epidermal hyperplasia, systemic immune activation, and cytokine levels, while showing favorable biosafety. Together, these publications portray upadacitinib as a therapy under active investigation for durable disease control, comparative benefit-risk assessment, formulation equivalence, and novel combination delivery approaches across multiple immune-mediated conditions.

Key Publications

• NEWJun Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. (RMD open, 2026, PMID 42342288): "To assess the safety and efficacy of upadacitinib versus adalimumab through 7 years in the ongoing SELECT-COMPARE study."
• Jun A combination therapy strategy: precision co-targeting of CCR7 and JAK1 with a smart hydrogel for inflammatory skin diseases. (Journal of nanobiotechnology, 2026, PMID 42237357): "A pH-responsive hydrogel (C-P@U/C-siCCR7) was designed for co-delivery of CCR7-targeting siRNA and the JAK1 inhibitor upadacitinib (UPA)."
• Jun Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (The Journal of dermatological treatment, 2026, PMID 42223292): "using data from the 24-week Heads Up trial comparing dupilumab versus upadacitinib in adults with moderate-to-severe AD."
• Jun Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment. (Clinical pharmacology in drug development, 2026, PMID 42212538): "The aim of this study is to evaluate the pharmacokinetic characteristics, bioequivalence, and safety of two brands of upadacitinib (UPA) extended-release tablets (15 mg) in healthy Chinese subjects under fasting and postprandial conditions."
• May Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). (Dermatology and therapy, 2026, PMID 42213297): "This study aimed to characterise temporal patterns of clinical response in patients with AD treated with dupilumab or upadacitinib in routine clinical practice."
• May Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials. (The Journal of dermatological treatment, 2026, PMID 42112622): "The objective of the current study was to assess the long-term impact of upadacitinib, a once-daily oral selective Janus kinase inhibitor approved for the treatment of moderate-to-severe AD, on patient-reported outcomes, providing a comprehensive in-depth evaluation of results of patient experience across multiple domains."
• May Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. (Advances in therapy, 2026, PMID 42105145): "Tofacitinib, filgotinib, and upadacitinib are Janus kinase inhibitors (JAKis) available for ulcerative colitis (UC) refractory or intolerant to at least one advanced therapy; their comparative effectiveness in clinical practice remains uncertain."
• May Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry. (United European gastroenterology journal, 2026, PMID 42057704): "Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD)."
• Jun Real-World Safety of JAK Inhibitors in Skin Immune-Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study. (Clinical pharmacology and therapeutics, 2026, PMID 41830903): "Patients newly prescribed JAKis (tofacitinib, upadacitinib, deucravacitinib, baricitinib, abrocitinib, or ritlecitinib) were propensity score-matched (1:1) with those prescribed cIMs (methotrexate or cyclosporine) based on demographics, baseline skin IMIDs, and comorbidities, yielding 17,068 matched patients."
• Jun Successful treatment of tofacitinib-refractory scleritis associated with multiple systemic inflammatory diseases using upadacitinib. (Immunological medicine, 2026, PMID 41263666): "...the possibility of transitioning to a selective JAK1 inhibitor in cases of pan-JAKi resistance."